Weak Near-Term Market Outlook: DRL Among Ajit Mishra’s Top 3 Picks

Market Sentiment Weakens as Ajit Mishra Highlights Dr. Reddy’s Laboratories

Investors are advised to adopt a cautious stance amid a weakening market outlook, with Dr. Reddy’s Laboratories emerging as a key stock pick.

Market Overview: A Fragile Recovery

The Indian equity markets experienced a sharp reversal on Wednesday, with the Nifty index closing down 0.88% at 22,687.50. This decline highlights the fragility of the recent recovery, as profit booking and macroeconomic concerns overshadowed initial gains driven by strong performances in IT stocks and Reliance Industries. The broader market, particularly midcap and smallcap indices, faced even steeper declines, reflecting a pervasive risk aversion among investors.

Global factors, including elevated Brent crude prices hovering around $110 per barrel and geopolitical tensions, have contributed to a cautious sentiment. While the Indian rupee has shown some strength, concerns over oil prices, global bond yields, and foreign fund flows remain significant risks. As the earnings season unfolds, investors are closely monitoring corporate results and management commentary for insights into future performance.

Sector Performance and Technical Indicators

On the sectoral front, all sectors except IT ended in the red, with metals, auto, and energy stocks among the hardest hit. The Nifty’s decline below its 20-day exponential moving average (20-DEMA) has further weakened the near-term outlook, with the 22,200–22,400 zone identified as a critical support area. Conversely, resistance is expected around the 23,000–23,300 range during any potential recovery.

Given the current market dynamics, Mishra advises investors to maintain a cautious stance and focus on selective stock-specific opportunities. The ongoing volatility necessitates a balanced approach, with appropriate positioning on both sides of the market.

Top Stock Picks: Dr. Reddy’s Laboratories and Others

Among Mishra’s top stock recommendations, Dr. Reddy’s Laboratories stands out. Currently trading at ₹1244.5, the stock is advised for accumulation with a target of ₹1335 and a stop-loss at ₹1197. Dr. Reddy’s has shown resilience after recovering from a crucial multi-year support zone and reclaiming the 200-day exponential moving average (200-EMA). The formation of a steady base in a triangular pattern suggests a potential trend reversal, with a decisive move above ₹1250 likely to accelerate upward momentum.

In addition to Dr. Reddy’s, Mishra recommends Coforge, currently priced at ₹1951, with a target of ₹2090 and a stop-loss at ₹1880. The stock has been trading in a steady uptrend, supported by positive sectoral momentum. Conversely, Dixon Technologies (India), trading at ₹11730, is recommended for a sell position, targeting ₹11300 with a stop-loss at ₹11950, as the stock has shown sustained selling pressure.

Key Highlights

• Market sentiment remains weak, with the Nifty closing below 22,700.
• Dr. Reddy’s Laboratories is recommended as a buy with a target of ₹1335.
• Coforge shows strength in IT, with a target of ₹2090.
• Dixon Technologies is under pressure, recommended for a sell position.
• Global macroeconomic factors continue to impact market performance.

Investor Note: As market volatility persists, investors should remain cautious and focus on selective opportunities, particularly in stocks like Dr. Reddy’s Laboratories that show potential for recovery amidst broader market challenges.